This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -66% and 66.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -12.90% and 10.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Invo BioScience Inc. (INVO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Invo BioScience Inc. (INVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Invo BioScience Inc. (INVO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Invo BioScience Inc. (INVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 37.50% and 11.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Invo BioScience Inc. (INVO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invo BioScience Inc. (INVO) delivered earnings and revenue surprises of -20.00% and -13.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Invo BioScience Inc. (INVO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Invo BioScience Inc. (INVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invo BioScience Inc. (INVO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invo BioScience Inc. (INVO) delivered earnings and revenue surprises of 10.53% and -0.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Invo BioScience Inc. (INVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Invo BioScience Inc. (INVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for May 21st
by Zacks Equity Research
ATHM, INVO, FOUR, KRYS, and RMAX have been added to the Zacks Rank #5 (Strong Sell) List on May 21, 2021
New Strong Sell Stocks for April 16th
by Zacks Equity Research
VNET, ALTG, FPI, HALL, and INVO have been added to the Zacks Rank #5 (Strong Sell) List on April 16, 2021